Industry news

  • 24 March 2017

    Pharma's rep with patient groups was on the rise, but not anymore: PatientView

    Beth Snyder Bulik / FiercePharmaMarketing

    It may have been too good to last. After an upswing in pharma's global reputation in 2015, its standing among patient groups has swung the other way—again. Only 38% of patient groups said the industry had either an “excellent” or “good” reputation, down from almost 45% last year.

  • 23 March 2017

    Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results

    Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results

    Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016. “We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017,” said Mr. Jeffrey M. Nugent, a member of Neothetics’ Operating Committee and Board of Directors.

  • 23 March 2017

    New blood biomarker could enhance early detection of heart attack risk

    Arlene Weintraub / FierceBiotech

    When it comes to predicting who’s at risk of suffering a heart attack or other major cardiac events, physicians have long relied on detecting high levels of C-reactive protein (CRP), an inflammatory biomarker. But new research suggests CRP may not be the only game in town.

  • 23 March 2017

    Big Pharma finds a hit with disease awareness social media posts in 2016

    Beth Snyder Bulik / FiercePharmaMarketing

    Pharma marketers continued to up their social media game in 2016, according to a new report, with many embracing disease awareness and charitable causes to drive engagement across social networks.

  • 22 March 2017

    Doctors in New Zealandthe only non-U.S. country that allows DTC advertisingcall for bans

    Beth Snyder Bulik / FiercePharmaMarketing

    Just like the United States does, New Zealand allows DTC pharma advertising. And just like in the U.S., many doctors there would like to ban the ads. Both the Royal New Zealand College of General Practitioners and the New Zealand Medical Association have come out recently with statements against DTC ads, as reported in New Zealand Doctor magazine. Both groups have called for a total ban on DTC ads, much the way the American Medical Association and American Society of Health-System Pharmacists did in the U.S.

  • 22 March 2017

    Whats on biopharmas auction block? EY tracks a growing appetite for pipeline divestment deals

    John Carroll / Endpoints News

    Last fall the research arm of the Financial Times went out and took the industry’s pulse on dealmaking. And they found that there’s been a big increase in appetite for divestments in the life sciences business, according to the EY M&A Outlook and Firepower Report 2017.

  • 21 March 2017

    Google made investment in new antibiotics startup

    GMP News

    GV, the venture capital arm of Google, led an estimated $51 million investment round in Spero Therapeutics, a Cambridge, Massachusetts-based biotech developing a new class of antibiotic treatments targeting some of the toughest drug-resistant bacterial infections.

  • 21 March 2017

    Big Data: Is It Crunch Time for Pharma?

    Julian Upton / Pharmaceutical Executive

    With big data and advanced analytics progressing from fad to frontier status, Pharm Exec examines the readiness of the biopharma industry to take advantage of this promise. Can new digital health tools be harnessed to help advance new treatment approaches and aid decision-making? 

  • 20 March 2017

    Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat

    Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat

    Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced completion of subject enrollment for its Phase 2 proof of concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat.  

  • 20 March 2017

    The UK's Catapult to Drug Discovery Collaboration

    Julian Upton / Pharmaceutical Executive

    Pharm Exec speaks to Chris Molloy, CEO of the Medicines Discovery Catapult, about how the organization aims to establish new approaches that draw on the combined strengths of the UK’s private, public and not-for-profit sectors to grow and sustain the country’s reputation for innovative, fast-to-patient drug discovery.

All Partners

All Portfolio

MEDIA CENTER

  • Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

All news